Netherlands · Delayed Price · Currency is EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 1.00 billion. The enterprise value is 972.33 million.
| Market Cap | 1.00B |
| Enterprise Value | 972.33M |
Important Dates
The last earnings date was Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 685.15 million shares outstanding. The number of shares has decreased by -2.65% in one year.
| Current Share Class | 685.15M |
| Shares Outstanding | 685.15M |
| Shares Change (YoY) | -2.65% |
| Shares Change (QoQ) | -26.83% |
| Owned by Insiders (%) | 2.11% |
| Owned by Institutions (%) | 17.30% |
| Float | 670.71M |
Valuation Ratios
The trailing PE ratio is 3,078.73 and the forward PE ratio is 25.25.
| PE Ratio | 3,078.73 |
| Forward PE | 25.25 |
| PS Ratio | 3.25 |
| PB Ratio | 4.44 |
| P/TBV Ratio | 9.07 |
| P/FCF Ratio | 22.31 |
| P/OCF Ratio | 22.05 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.58, with an EV/FCF ratio of 21.64.
| EV / Earnings | 2,986.47 |
| EV / Sales | 3.15 |
| EV / EBITDA | 22.58 |
| EV / EBIT | 28.03 |
| EV / FCF | 21.64 |
Financial Position
The company has a current ratio of 3.16, with a Debt / Equity ratio of 0.49.
| Current Ratio | 3.16 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | 2.55 |
| Debt / FCF | 2.48 |
| Interest Coverage | 2.90 |
Financial Efficiency
Return on equity (ROE) is 0.03% and return on invested capital (ROIC) is 6.92%.
| Return on Equity (ROE) | 0.03% |
| Return on Assets (ROA) | 5.76% |
| Return on Invested Capital (ROIC) | 6.92% |
| Return on Capital Employed (ROCE) | 10.74% |
| Revenue Per Employee | 764,273 |
| Profits Per Employee | 806 |
| Employee Count | 404 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 0.57 |
Taxes
In the past 12 months, Pharming Group has paid 12.49 million in taxes.
| Income Tax | 12.49M |
| Effective Tax Rate | 99.53% |
Stock Price Statistics
The stock price has increased by +104.33% in the last 52 weeks. The beta is 0.19, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +104.33% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.00 |
| Relative Strength Index (RSI) | 63.10 |
| Average Volume (20 Days) | 21,154,271 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 308.77 million and earned 325,579 in profits. Earnings per share was 0.00.
| Revenue | 308.77M |
| Gross Profit | 277.59M |
| Operating Income | 35.33M |
| Pretax Income | 12.55M |
| Net Income | 325,579 |
| EBITDA | 40.84M |
| EBIT | 35.33M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 141.62 million in cash and 111.58 million in debt, giving a net cash position of 30.04 million or 0.04 per share.
| Cash & Cash Equivalents | 141.62M |
| Total Debt | 111.58M |
| Net Cash | 30.04M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 225.56M |
| Book Value Per Share | 0.45 |
| Working Capital | 161.67M |
Cash Flow
In the last 12 months, operating cash flow was 45.45 million and capital expenditures -519,903, giving a free cash flow of 44.93 million.
| Operating Cash Flow | 45.45M |
| Capital Expenditures | -519,903 |
| Free Cash Flow | 44.93M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 89.90%, with operating and profit margins of 11.44% and 0.11%.
| Gross Margin | 89.90% |
| Operating Margin | 11.44% |
| Pretax Margin | 4.06% |
| Profit Margin | 0.11% |
| EBITDA Margin | 13.23% |
| EBIT Margin | 11.44% |
| FCF Margin | 14.55% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.65% |
| Shareholder Yield | 2.65% |
| Earnings Yield | 0.03% |
| FCF Yield | 4.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 2.65 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.65 |
| Piotroski F-Score | 6 |